Article ; Online: Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.
2015 Volume 75, Issue 22, Page(s) 4742–4752
Abstract: Malignant ascites is a common complication in the late stages of epithelial ovarian cancer (EOC ... in the pathogenesis of malignant ascites, we blocked macrophage function in ID8 mice using a colony-stimulating factor ... of malignant ascites using fluid from human patients and an immunocompetent murine model (ID8) of EOC ...
| Abstract | Malignant ascites is a common complication in the late stages of epithelial ovarian cancer (EOC) that greatly diminishes the quality of life of patients. Malignant ascites is a known consequence of vascular dysfunction, but current approved treatments are not effective in preventing fluid accumulation. In this study, we investigated an alternative strategy of targeting macrophage functions to reverse the vascular pathology of malignant ascites using fluid from human patients and an immunocompetent murine model (ID8) of EOC that mirrors human disease by developing progressive vascular disorganization and leakiness culminating in massive ascites. We demonstrate that the macrophage content in ascites fluid from human patients and the ID8 model directly correlates with vascular permeability. To further substantiate macrophages' role in the pathogenesis of malignant ascites, we blocked macrophage function in ID8 mice using a colony-stimulating factor 1 receptor kinase inhibitor (GW2580). Administration of GW2580 in the late stages of disease resulted in reduced infiltration of protumorigenic (M2) macrophages and dramatically decreased ascites volume. Moreover, the disorganized peritoneal vasculature became normalized and sera from GW2580-treated ascites protected against endothelial permeability. Therefore, our findings suggest that macrophage-targeted treatment may be a promising strategy toward a safe and effective means to control malignant ascites of EOC. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Animals ; Anisoles/pharmacology ; Ascites/etiology ; Ascites/prevention & control ; Capillary Permeability/drug effects ; Carcinoma, Ovarian Epithelial ; Cell Line, Tumor ; Disease Models, Animal ; Female ; Flow Cytometry ; Humans ; Immunohistochemistry ; Macrophages/drug effects ; Mice ; Neoplasms, Glandular and Epithelial/complications ; Ovarian Neoplasms/complications ; Pyrimidines/pharmacology ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors | |||||
| Chemical Substances | 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine ; Anisoles ; Csf1r protein, mouse ; Pyrimidines ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | |||||
| Language | English | |||||
| Publishing date | 2015-10-15 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 1432-1 | |||||
| ISSN | 1538-7445 ; 0008-5472 | |||||
| ISSN (online) | 1538-7445 | |||||
| ISSN | 0008-5472 | |||||
| DOI | 10.1158/0008-5472.CAN-14-3373 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.135/5: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.